TY - JOUR
T1 - Relationship between treatment initiation and healthcare costs in Alzheimer's disease
AU - Black, Christopher M.
AU - Lipton, Richard B.
AU - Thiel, Ellen
AU - Brouillette, Matthew
AU - Khandker, Rezaul
N1 - Funding Information:
This study was funded by Merck & Co., Inc. Medical writing support was provided by Jessamine P. Winer-Jones, Ph.D. of IBM Watson Health. These services were paid for by Merck & Co., Inc.
Publisher Copyright:
© 2019 - IOS Press and the authors. All rights reserved.
PY - 2019
Y1 - 2019
N2 - The relationship between Alzheimer's disease (AD) treatment patterns and healthcare costs is unknown. Administrative claims data from the MarketScan Commercial and Medicare databases covering 2010 through 2016 were used to identify the comorbidities, treatment patterns, and healthcare costs in the three years prior to and one year post medical diagnosis of AD in 21,448 patients with no treatment and 57,970 patients with treatment. Pre-index mean annual costs ranged from 14,228 to 26,876, and post-index mean annual costs ranged from 21,052 to 45,685 depending on age and treatment timing. After adjusting for baseline characteristics, patients 50-100 years old who initiated treatment with an FDA approved drug prior to or concurrent with diagnosis had healthcare costs 9%-19% lower in the year following diagnosis than those who did not receive treatment. Early or concurrent treatment is associated with lower overall healthcare costs in the year following AD diagnosis.
AB - The relationship between Alzheimer's disease (AD) treatment patterns and healthcare costs is unknown. Administrative claims data from the MarketScan Commercial and Medicare databases covering 2010 through 2016 were used to identify the comorbidities, treatment patterns, and healthcare costs in the three years prior to and one year post medical diagnosis of AD in 21,448 patients with no treatment and 57,970 patients with treatment. Pre-index mean annual costs ranged from 14,228 to 26,876, and post-index mean annual costs ranged from 21,052 to 45,685 depending on age and treatment timing. After adjusting for baseline characteristics, patients 50-100 years old who initiated treatment with an FDA approved drug prior to or concurrent with diagnosis had healthcare costs 9%-19% lower in the year following diagnosis than those who did not receive treatment. Early or concurrent treatment is associated with lower overall healthcare costs in the year following AD diagnosis.
KW - Administrative claims
KW - Alzheimer's disease
KW - Delayed diagnosis
KW - Healthcare costs
KW - Time-To-Treatment
UR - http://www.scopus.com/inward/record.url?scp=85064862316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064862316&partnerID=8YFLogxK
U2 - 10.3233/JAD-180983
DO - 10.3233/JAD-180983
M3 - Article
C2 - 30909221
AN - SCOPUS:85064862316
SN - 1387-2877
VL - 68
SP - 1575
EP - 1585
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 4
ER -
